A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing different doses of the investigational drug tirzepatide in adults with type 2 diabetes and obesity to see how it affects body weight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 414 people

Who can join Ages 18–75 · all sexes

Timeline Started 2023-09 · est. completion 2026-10

Where 40 sites · Argentina, Mexico, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT06037252 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06037252 ↗